Today is Duchenne Awareness Day #WDAD2021. Duchenne Muscular Dystrophy (DMD) is a devastating genetic disease characterized by progressive muscle degeneration, for which there is no cure. Most patients are diagnosed between the age of 2-5 years old and currently have a life expectancy of 30 years in the western world.

Press Release NTrans investment v20210527 NTrans Technologies closes Series A investment to accelerate development of gene editing therapy.   May 27, 2021   Utrecht, The Netherlands – NTrans Technologies (NTrans), a leader in gene editing technologies, today announced a Series A investment of 2 million Euros, led by Essential Investments,

NTrans has successfully completed the H2020-ENTRANCE project. The results of the project have been publised on the CORDIS website in six languages at:  https://cordis.europa.eu/article/id/415539-itop-technology-for-protein-delivery-into-cells?WT.mc_id=exp NTrans researchers have optimised the composition of iTOP and developed protocols for the most effective transfection of various cell types including cell lines, stem cells and

Last May at the BCF Career Event NTrans Technologies has been awarded the BCF Scale-up Award. What is the story behind this upcoming life science business? https://www.bcfcareer.nl/bcf-scale-up-award-winner-2019/ The story of NTrans Technologies starts in 2015 in the laboratories of the Hubrecht Institute of the Royal Netherlands Academy of Sciences (NWO).

John van der Oost (Scientific Advisor and Co-founder) of NTrans Technologies about CRISPR-Cas technology in “Analyse Nederland”: https://analysenederland.nl/article/john-van-der-oost-darwin-zou-crispr-cas-technologie-juist-fantastisch-vinden.html

On February 12th and 13th, the kick-off of an international, 15-million-euro, 20-partner project titled iPSpine (Induced pluripotent stem cell-based therapy for spinal regeneration) was held in Utrecht, The Netherlands. This 5-year project falls under the European Union’s Horizon 2020 programme to fund research that improves knowledge, testing, and exploitation platforms that address the future of

NTrans Technologies today announced it has been awarded a prestigious, €1.5M EU SME instrument grant. NTrans Technologies is a spin-off company that emerged from research of the Hubrecht Institute. The company is based on a proprietary technology (iTOP), which allows the intracellular delivery of therapeutic proteins in a wide range

NTrans Technologies wins the AXON Innovation for Health Award 2017 On Thursday 16 February during the fourth edition of the annual Innovation for Health conference in WTC Rotterdam, Marco de Boer of NTrans Technologies won the AXON Innovation for Health Award 2017 for the best innovation pitch presentation. NTrans Technologies

Cell 161(3):674-690 · April 2015 Modulation of protein function is used to intervene in cellular processes but is often done indirectly by means of introducing DNA or mRNA encoding the effector protein. Thus far, direct intracellular delivery of proteins has remained challenging. We developed a method termed iTOP, for induced